A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC
Status:
Completed
Trial end date:
2018-11-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether a brief course of radiation therapy given to
one area affected by the cancer will improve the chances of responding to immuno-therapy in
the form of a medicine called MPDL3280A, an antibody against PD-L1. PD-L1 is expressed on
lung cancers and is known to block the effects of the body's immune system in attacking the
cancer. Blocking this PD-L1 has been shown to improve the body's immune cells to attack and
kill the cancer cells in non-small cell lung cancer. The goal of this study is to see if
prior treatment with radiation will allow improved recognition of the cancer by the body's
immune cells in the presence of MPDL3280A.
Phase:
Early Phase 1
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center